Published in Am J Ophthalmol on February 01, 2008
Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med (2011) 19.42
Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis (2012) 4.42
Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care (2010) 3.29
One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration. Am J Ophthalmol (2014) 2.24
Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP). Graefes Arch Clin Exp Ophthalmol (2009) 2.19
Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab. Eye (Lond) (2011) 2.05
Bimonthly injections of ranibizumab for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (2014) 2.04
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev (2014) 1.76
Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol (2014) 1.41
A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard. PLoS One (2012) 1.38
Critical appraisal of ranibizumab in the treatment of diabetic macular edema. Clin Ophthalmol (2013) 1.23
Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity. Graefes Arch Clin Exp Ophthalmol (2010) 1.21
Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration. Indian J Ophthalmol (2011) 1.20
Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema. Clin Ophthalmol (2014) 1.20
Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol (2008) 1.20
Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. Cochrane Database Syst Rev (2008) 1.17
A protocol for the retina surgeon's safe initial intravitreal injections. Clin Ophthalmol (2010) 1.14
Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (2012) 1.11
Drug-induced uveitis. J Ophthalmic Inflamm Infect (2013) 1.11
Prevalence and incidence of blindness and other degrees of sight impairment in patients treated for neovascular age-related macular degeneration in a well-defined region of the United Kingdom. Eye (Lond) (2015) 1.11
Long-term visual course after anti-VEGF therapy for exudative AMD in clinical practice evaluation of the German reinjection scheme. Graefes Arch Clin Exp Ophthalmol (2010) 1.09
Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug. Br J Ophthalmol (2012) 1.06
Outcome of ranibizumab treatment in neovascular age related macula degeneration in eyes with baseline visual acuity better than 6/12. Eye (Lond) (2011) 1.06
Management of retinal vascular diseases: a patient-centric approach. Eye (Lond) (2012) 1.05
Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov (2016) 1.03
Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability. J Ophthalmol (2011) 1.02
Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. Br J Ophthalmol (2012) 1.01
Intravitreal crystalline drug delivery for intraocular proliferation diseases. Invest Ophthalmol Vis Sci (2009) 1.01
Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research. Graefes Arch Clin Exp Ophthalmol (2014) 1.01
Quantitative subanalysis of cystoid spaces and outer nuclear layer using optical coherence tomography in age-related macular degeneration. Invest Ophthalmol Vis Sci (2009) 1.00
One-year outcomes using ranibizumab for neovascular age-related macular degeneration: results of a prospective and retrospective observational multicentre study. J Ophthalmol (2011) 0.99
Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema. Clin Interv Aging (2013) 0.99
Treatment of neovascular age-related macular degeneration: Current therapies. Clin Ophthalmol (2009) 0.99
One-year results of intravitreal ranibizumab for neovascular age-related macular degeneration and clinical responses of various subgroups. Jpn J Ophthalmol (2009) 0.99
Efficacy and safety of widely used treatments for macular oedema secondary to retinal vein occlusion: a systematic review. BMC Ophthalmol (2014) 0.98
Aflibercept in wet AMD: specific role and optimal use. Drug Des Devel Ther (2013) 0.97
Antivascular endothelial growth factor agents for neovascular age-related macular degeneration. J Ophthalmol (2011) 0.97
Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting. Clin Ophthalmol (2012) 0.97
High-speed ultrahigh resolution optical coherence tomography before and after ranibizumab for age-related macular degeneration. Ophthalmology (2009) 0.96
Diabetic angiopathy and angiogenic defects. Fibrogenesis Tissue Repair (2012) 0.96
Bevacizumab versus ranibizumab in the treatment of exudative age-related macular degeneration. Int Ophthalmol (2009) 0.95
How the comparison of age-related macular degeneration treatments trial results will impact clinical care. Am J Ophthalmol (2011) 0.95
Prospective study evaluating the predictability of need for retreatment with intravitreal ranibizumab for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (2012) 0.95
Tunable sustained intravitreal drug delivery system for daunorubicin using oxidized porous silicon. J Control Release (2014) 0.93
Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab. Jpn J Ophthalmol (2010) 0.93
Epidemiological and Clinical Baseline Characteristics as Predictive Biomarkers of Response to Anti-VEGF Treatment in Patients with Neovascular AMD. J Ophthalmol (2016) 0.92
Results of flexible ranibizumab treatment in age-related macular degeneration and search for parameters with impact on outcome. Graefes Arch Clin Exp Ophthalmol (2011) 0.91
Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular Degeneration. J Ophthalmol (2012) 0.90
The role of spectral-domain OCT in the diagnosis and management of neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging (2011) 0.90
Variants in the APOE gene are associated with improved outcome after anti-VEGF treatment for neovascular AMD. Invest Ophthalmol Vis Sci (2011) 0.90
Antiangiogenic therapy for ischemic retinopathies. Cold Spring Harb Perspect Med (2012) 0.89
Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy. Mediators Inflamm (2013) 0.89
Antiangiogenic drugs in the management of ocular diseases: Focus on antivascular endothelial growth factor. Clin Ophthalmol (2010) 0.89
Comparison of long-acting bevacizumab formulations in the treatment of choroidal neovascularization in a rat model. J Ocul Pharmacol Ther (2011) 0.89
Serum concentration of vascular endothelial growth factor after bilateral intravitreal injection of bevacizumab. Korean J Ophthalmol (2014) 0.88
[New aspects in the therapy of neovascular age related macular degeneration. Current position of the Retinological Society, the Germany Ophthalmologic Society and the Professional Union of Eye Doctors of Germany]. Ophthalmologe (2009) 0.88
Defining response to anti-VEGF therapies in neovascular AMD. Eye (Lond) (2015) 0.88
The effects of nepafenac and amfenac on retinal angiogenesis. Brain Res Bull (2009) 0.88
Retention of good visual acuity in eyes with neovascular age-related macular degeneration and chronic refractory subfoveal subretinal fluid. Saudi J Ophthalmol (2014) 0.88
Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years. Graefes Arch Clin Exp Ophthalmol (2010) 0.87
Biocompatible reverse thermal gel sustains the release of intravitreal bevacizumab in vivo. Invest Ophthalmol Vis Sci (2014) 0.87
Anti-VEGF therapies in the treatment of choroidal neovascularisation secondary to non-age-related macular degeneration: a systematic review. BMJ Open (2015) 0.87
Effectiveness of ranibizumab intravitreal injections for exudative age-related macular degeneration treatment: 12-month outcomes. Med Sci Monit (2011) 0.87
Use of nepafenac (Nevanac) in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injections. Clin Ophthalmol (2010) 0.87
Persistent suppression of ocular neovascularization with intravitreal administration of AAVrh.10 coding for bevacizumab. Hum Gene Ther (2011) 0.86
Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe? Clin Interv Aging (2009) 0.86
Bevacizumab treatment for choroidal neovascularization due to age-related macular degeneration in Japanese patients. Jpn J Ophthalmol (2010) 0.86
Functional and anatomical outcome of eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab following an exit strategy regimen. Br J Ophthalmol (2014) 0.86
A prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration. Clin Ophthalmol (2012) 0.85
Ranibizumab for the treatment of wet AMD: a summary of real-world studies. Eye (Lond) (2015) 0.85
IKK2 inhibition attenuates laser-induced choroidal neovascularization. PLoS One (2014) 0.85
FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity. Graefes Arch Clin Exp Ophthalmol (2012) 0.85
Aflibercept for the treatment of age-related macular degeneration. Ophthalmol Ther (2013) 0.85
Current status of anti-vascular endothelial growth factor therapy in Europe. Jpn J Ophthalmol (2008) 0.85
TIMP-2 modulates VEGFR-2 phosphorylation and enhances phosphodiesterase activity in endothelial cells. Lab Invest (2010) 0.85
Simple estimation of clinically relevant lesion volumes using spectral domain-optical coherence tomography in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci (2011) 0.84
Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen. Br J Ophthalmol (2014) 0.84
Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: an instrumental variable analysis of the AURA study. Eye (Lond) (2016) 0.84
Long-Term Visual Outcome in Wet Age-Related Macular Degeneration Patients Depending on the Number of Ranibizumab Injections. J Ophthalmol (2015) 0.84
Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study. Br J Ophthalmol (2016) 0.84
Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in development. Clin Ophthalmol (2015) 0.83
Optical coherence tomography-based intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Int Ophthalmol (2010) 0.83
Lucentis using Visudyne study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration. Clin Ophthalmol (2010) 0.83
Treatment of age-related macular degeneration: beyond VEGF. Jpn J Ophthalmol (2010) 0.83
Anatomic response of occult choroidal neovascularization to intravitreal ranibizumab: a study by indocyanine green angiography. Graefes Arch Clin Exp Ophthalmol (2011) 0.83
In-vivo investigation of laser-induced choroidal neovascularization in rat using spectral-domain optical coherence tomography (SD-OCT). Graefes Arch Clin Exp Ophthalmol (2012) 0.83
Temporal pattern of resolution/recurrence of choroidal neovascularization during bevacizumab therapy for wet age-related macular degeneration. Int J Ophthalmol (2013) 0.83
Impact of loading phase, initial response and CFH genotype on the long-term outcome of treatment for neovascular age-related macular degeneration. PLoS One (2012) 0.83
Aflibercept in wet age-related macular degeneration: a perspective review. Ther Adv Chronic Dis (2012) 0.83
Individual recurrence intervals after anti-VEGF therapy for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (2010) 0.82
Implantable MicroPump for Drug Delivery in Patients with Diabetic Macular Edema. Transl Vis Sci Technol (2014) 0.82
Three-year follow-up of visual outcome and quality of life in patients with age-related macular degeneration. Clin Ophthalmol (2013) 0.81
Retracted Potential role of lampalizumab for treatment of geographic atrophy. Clin Ophthalmol (2015) 0.81
Characteristics of eyes with secondary loss of visual acuity receiving variable dosing ranibizumab for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (2011) 0.81
In vivo imaging of choroidal angiogenesis using fluorescence-labeled cationic liposomes. Mol Vis (2012) 0.81
Optical coherence tomography changes before the development of choroidal neovascularization in second eyes of patients with bilateral wet macular degeneration. Eye (Lond) (2011) 0.81
Single-session photodynamic therapy combined with intravitreal ranibizumab for neovascular age-related macular degeneration: a comprehensive functional retinal assessment. Doc Ophthalmol (2013) 0.81
[Therapy of stage III retinal angiomatous proliferation. Intravitreal ranibizumab injections]. Ophthalmologe (2013) 0.80
25th RCOphth Congress, President's Session paper: 25 years of progress in medical retina. Eye (Lond) (2014) 0.80
Ranibizumab for neovascular age-related macular degeneration. N Engl J Med (2006) 30.63
Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med (2006) 20.84
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology (2012) 8.29
Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology (2009) 6.44
Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology (2012) 6.35
Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology (2006) 5.79
Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina (2006) 4.40
A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology (2009) 3.76
Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology (2010) 3.49
Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol (2007) 3.00
A recombineering pipeline for functional genomics applied to Caenorhabditis elegans. Nat Methods (2006) 2.87
Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology (2011) 2.78
Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. Ophthalmology (2009) 2.77
Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology (2012) 2.32
Oxidative stress and calcium signaling in the adverse effects of environmental particles (PM10). Free Radic Biol Med (2003) 2.28
One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology (2012) 2.20
Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology (2013) 2.13
Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology (2006) 2.07
Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol (2010) 2.05
Inspiratory loading intensity does not influence lactate clearance during recovery. Med Sci Sports Exerc (2012) 2.00
Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology (2012) 1.95
Absence of branches from xylan in Arabidopsis gux mutants reveals potential for simplification of lignocellulosic biomass. Proc Natl Acad Sci U S A (2010) 1.88
Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study. J Ophthalmic Inflamm Infect (2013) 1.85
The role of free radicals in the toxic and inflammatory effects of four different ultrafine particle types. Inhal Toxicol (2003) 1.83
Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology (2011) 1.79
Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina (2007) 1.68
Indocyanine green staining of anteriorly placed zonules. J Cataract Refract Surg (2003) 1.61
SAVE (Super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results. Ophthalmic Surg Lasers Imaging Retina (2013) 1.60
Solitary fibrous tumor of the orbit: is it rare? Report of a case series and review of the literature. Ophthalmology (2003) 1.58
The impact of different nanoparticle surface chemistry and size on uptake and toxicity in a murine macrophage cell line. Toxicol Appl Pharmacol (2008) 1.50
Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology (2010) 1.49
Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology (2012) 1.48
Synthetic generation of influenza vaccine viruses for rapid response to pandemics. Sci Transl Med (2013) 1.47
Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology (2005) 1.47
Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci U S A (2011) 1.47
Optical coherence tomography of the suprachoroid after CyPass Micro-Stent implantation for the treatment of open-angle glaucoma. Br J Ophthalmol (2013) 1.46
Spectral domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the "flying saucer" sign). Clin Ophthalmol (2010) 1.43
Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology (2006) 1.37
The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology (2011) 1.34
Population-based incidence of uveal melanoma in various races and ethnic groups. Am J Ophthalmol (2005) 1.33
Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: a phase I clinical trial. Ophthalmology (2010) 1.32
Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina (2012) 1.24
Role of vascular endothelial growth factor in ocular angiogenesis. Ophthalmol Clin North Am (2006) 1.22
Epstein-Barr virus-related bilateral acute retinal necrosis in a patient with X-linked lymphoproliferative disorder. Arch Ophthalmol (2003) 1.19
Visualizing vitreous using Kenalog suspension. J Cataract Refract Surg (2003) 1.19
Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. Ophthalmology (2011) 1.18
Cystoid macular edema secondary to albumin-bound paclitaxel therapy. Arch Ophthalmol (2008) 1.18
Intravitreal bevacizumab (avastin) in central retinal vein occlusion. Retina (2007) 1.10
Evaluating the uptake and intracellular fate of polystyrene nanoparticles by primary and hepatocyte cell lines in vitro. Toxicol Appl Pharmacol (2009) 1.09
An investigation into the potential for different surface-coated quantum dots to cause oxidative stress and affect macrophage cell signalling in vitro. Nanotoxicology (2010) 1.08
Early postoperative safety and surgical outcomes after implantation of a suprachoroidal micro-stent for the treatment of open-angle glaucoma concomitant with cataract surgery. J Cataract Refract Surg (2013) 1.08
GUX1 and GUX2 glucuronyltransferases decorate distinct domains of glucuronoxylan with different substitution patterns. Plant J (2013) 1.06
Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology (2010) 1.06
Prospective study of changes in bone mineral density and turnover in children after hematopoietic cell transplantation. J Clin Endocrinol Metab (2005) 1.02
The effects of serum on the toxicity of manufactured nanoparticles. Toxicol Lett (2010) 1.02
Selective laser trabeculoplasty as a replacement for medical therapy in open-angle glaucoma. Am J Ophthalmol (2005) 1.00
FlyGEM, a full transcriptome array platform for the Drosophila community. Genome Biol (2004) 1.00
Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study. Retina (2010) 1.00
Annual rates of arterial thromboembolic events in medicare neovascular age-related macular degeneration patients. Ophthalmology (2007) 0.96
Quantum dot cytotoxicity in vitro: an investigation into the cytotoxic effects of a series of different surface chemistries and their core/shell materials. Nanotoxicology (2010) 0.95
Precise montaging and metric quantification of retinal surface area from ultra-widefield fundus photography and fluorescein angiography. Ophthalmic Surg Lasers Imaging Retina (2014) 0.93
Metabolic engineering of Pseudomonas putida for methylmalonyl-CoA biosynthesis to enable complex heterologous secondary metabolite formation. Chem Biol (2006) 0.91
Organization of a United States county system for comprehensive acute stroke care. Stroke (2012) 0.91
Evaluation of a cancer survivorship protocol: transitioning patients to survivors. Clin J Oncol Nurs (2012) 0.91
Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study. Am J Ophthalmol (2012) 0.90
Prospective evaluation of the incidence and risk factors for the development of RPE tears after high- and low-dose ranibizumab therapy. Retina (2013) 0.89
Endophthalmitis after intravitreal injection: the importance of viridans streptococci. Retina (2011) 0.89
A case of primary adenocarcinoma of the lacrimal sac. Orbit (2005) 0.89
Triphendiol (NV-196), development of a novel therapy for pancreatic cancer. Anticancer Drugs (2011) 0.89
Development of a population suppression strain of the human malaria vector mosquito, Anopheles stephensi. Malar J (2013) 0.88
Ultrafine particles cause cytoskeletal dysfunctions in macrophages: role of intracellular calcium. Part Fibre Toxicol (2005) 0.88
Relating the physicochemical characteristics and dispersion of multiwalled carbon nanotubes in different suspension media to their oxidative reactivity in vitro and inflammation in vivo. Nanotoxicology (2010) 0.88
The effect of refurbishing a UK steel plant on PM10 metal composition and ability to induce inflammation. Respir Res (2005) 0.88
Use of nepafenac (Nevanac) in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injections. Clin Ophthalmol (2010) 0.87
Effectiveness of a combined home visiting and group intervention for low income African American mothers: the pride in parenting program. Matern Child Health J (2011) 0.86
Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: the wave of the future in cancer therapy. Cancer Nurs (2005) 0.86
Intrinsic cytotoxic effects of fluoroquinolones on human corneal keratocytes and endothelial cells. Curr Med Res Opin (2008) 0.85
Inflammation and gene expression in the rat lung after instillation of silica nanoparticles: effect of size, dispersion medium and particle surface charge. Toxicol Lett (2014) 0.85
Original sound compositions reduce anxiety in emergency department patients: a randomised controlled trial. Med J Aust (2011) 0.84
Stable hydrogen isotope ratios of lignin methoxyl groups as a paleoclimate proxy and constraint of the geographical origin of wood. New Phytol (2007) 0.84
The uptake and intracellular fate of a series of different surface coated quantum dots in vitro. Toxicology (2011) 0.84
Functional conservation of the hydrophobic domain of polypeptide 3AB between human rhinovirus and poliovirus. Virology (2003) 0.84
Phenoxodiol inhibits growth of metastatic prostate cancer cells. Prostate (2010) 0.84
Selected clinical comparisons of spectral domain and time domain optical coherence tomography. Ophthalmic Surg Lasers Imaging (2009) 0.84
Driving ability reported by neovascular age-related macular degeneration patients after treatment with ranibizumab. Ophthalmology (2012) 0.84
Two Year SAVE Outcomes: 2.0 mg ranibizumab for recalcitrant neovascular AMD. Ophthalmology (2013) 0.84
Comparison of spectral-domain and time-domain optical coherence tomography in the detection of neovascular age-related macular degeneration activity. Retina (2014) 0.83
Lucentis using Visudyne study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration. Clin Ophthalmol (2010) 0.83
Recurrent Mycobacterium marinum tenosynovitis of the wrist mimicking extraarticular synovial chondromatosis on MR images. Skeletal Radiol (2004) 0.82
Coagulation abnormalities following primary intracerebral hemorrhage. J Stroke Cerebrovasc Dis (2007) 0.82
Reduced alveolar macrophage migration induced by acute ambient particle (PM10) exposure. Cell Biol Toxicol (2007) 0.82
Diagnostic transvitreal fine-needle aspiration biopsy of small melanocytic choroidal tumors in nevus versus melanoma category. Trans Am Ophthalmol Soc (2002) 0.81
High-frequency ultrasound of anterior segment retinoblastoma. Am J Ophthalmol (2004) 0.81
CD8alpha+ dendritic cells prime TCR-peptide-reactive regulatory CD4+FOXP3- T cells. Eur J Immunol (2010) 0.81
Progressive retinal nonperfusion in ischemic central retinal vein occlusion. Retina (2015) 0.81
Pseudomonas aeruginosa endogenous endophthalmitis with choroidal abscess in a patient with cystic fibrosis. Retina (2005) 0.80
Comparison of the cardiovascular effects of unoprostone 0.15%, timolol 0.5% and placebo in healthy adults during exercise using a treadmill test. Acta Ophthalmol Scand (2002) 0.80